Yposkesi is one of the largest Contract Development & Manufacturing Organizations (CDMO) in Europe for gene therapy viral vector manufacturing. A spin-off from the world-class gene therapy pioneer Genethon, Yposkesi capitalizes on more than 20 years’ expertise in biotherapeutic research.
It offer customers a full service: bioprocess development (upstream and downstream processing), small/pilot to large-scale production, analytical development, GMP manufacturing of clinical lots of lentiviral and AAV (Adeno-Associated Virus) vectors and regulatory support.
Its current 50,000ft2 state-of-the-art facility designed for high efficiency houses four independent manufacturing suites for bulk drug substance and two fill & finish suites. It is doubling this footprint to 100,000ft2 to expand its capacity to support the clinical and future commercial needs of its clients.
Yposkesi invests significantly in bioprocessing innovation aimed at improving the cost-effectiveness of gene therapy manufacturing.
Founded in 2016 by patient association AFM-Telethon and the SPI investment fund from BpiFrance, the state-owned French investment bank, Yposkesi is driving its ambitions through the leadership of directors with an established track record in gene therapy and pharmaceutical GMP-biomanufacturing. The company is located in Corbeil-Essonnes, near Paris, and employs 160 industrial and technical specialists.